W Richard Staub III

President, Research & Development Solutions

Richard StaubRichard Staub is president of the Research & Development Solutions global business unit at IQVIA, where he leads the world’s largest contract research organization (CRO). Supported by high-powered information and technology assets, the clinical experts in R&D Solutions leverage comprehensive, evidence-driven trial design, accelerate site activation and patient recruitment, and optimize trial execution. Richard also serves as chair of the Research & Development Solutions Executive Committee.

Previously, Richard was president of Novella Clinical, a Quintiles company, a specialty clinical research organization acquired by Quintiles in 2013, and the leader of QuintilesIMS’s Global Functional Resourcing business. Joining Novella in 2004, he served as both president and CEO from 2008-13. Under his leadership, Novella became a distinctively agile, results-oriented CRO in the highly complex and fast-growing areas of specialty pharma and medical technology. Prior to joining Novella, he was senior vice president of global business development for one of the world’s largest CROs. Richard’s career in the pharmaceutical industry began at Zeneca Pharmaceuticals in 1989 where he was given increasing responsibilities as a medical and hospital sales representative, cardiovascular portfolio analyst and marketing manager.

Richard holds a bachelor’s degree in Economics from the University of North Carolina at Chapel Hill.

 
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.

IQVIA Institute Inquiries

We are ready to help you better understand and benefit from the work of the IQVIA Institute for Human Data Science. Please get in touch today to learn more. 

Media Inquiries

Please use this form to reach out to our media team with inquiries. Thank you.